Bristol Myers touts pharma's biggest AI. It's the third.

Bristol Myers Squibb, one of the biggest US drugmakers, said Monday it's expanding its Nvidia AI setup enough to have — in the two companies' words — 'the most powerful AI factory in life sciences.' In plain English: BMS is buying a lot more of Nvidia's newest chips to help design new drugs. This is now the third pharma to make that same 'biggest' claim in about nine months.

STAT News flagged the pattern plainly: BMS is the third drugmaker in roughly nine months to announce it's building the biggest AI cluster in the industry. What's happening is that Nvidia has one flagship product line — the DGX SuperPOD — and every big pharma company is buying essentially the same version of it, then racing to be the one that gets to announce it. The hardware really is impressive. Drug design really does benefit from more computing power. But whether any of these AI factories will actually shrink the time it takes to bring a new medicine to patients — the thing that would matter to anyone outside pharma marketing — is a question none of them has answered yet.

Keep reading — what to watch

So what's actually worth watching? Not the next 'biggest' announcement — those will keep coming. Watch instead for the first pharma company to say something concrete: a drug candidate that reached trials faster because of the AI setup, or a target that the machine found and human researchers missed. Nine months of 'biggest' announcements have produced no such data. When it does come — and it might, because these machines really are new and really are more powerful — the story stops being about Nvidia and starts being about which drugmaker actually knows how to use one of these.